Inositol (Myo / D-Chiro)
SupplementThe medical score and community score are closely aligned. The clinical evidence [s6, s7, s12] and user experiences [c1, c2] agree on the core finding: inositol works reliably, particularly in PCOS and insulin resistance. The slight divergence arises because clinical studies show more consistent effects on metabolic endpoints than the more heterogeneous subjective reports regarding mood and OCD [s8, c3].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Inositol — particularly myo-inositol and the 40:1 MI:DCI combination — is one of the better-evidenced supplements for PCOS, insulin resistance, and anxiety disorders, backed by multiple meta-analyses and consistent RCT data. For PCOS it frequently restores cycle regularity and improves insulin sensitivity; psychiatric indications (panic disorder, OCD) require higher doses of 12–18 g/day. One critical nuance: high-dose D-chiro-inositol alone can raise androgen levels and trigger hair loss — the 40:1 ratio is physiologically grounded, not marketing. Overall safety profile is favorable; GI side effects early on are common but typically transient.
Description
Inositol (Myo and D-Chiro) is a vitamin-like compound with well-documented effects in PCOS, insulin resistance, anxiety disorders, and fertility [s1, s4, s7].
Inositol is a sugar-like cyclohexane derivative occurring in nine stereoisomeric forms. The two biologically most relevant forms are myo-inositol (MI) and D-chiro-inositol (DCI) [s1]. MI is the most abundant form in the human body and is particularly present in glucose-consuming tissues such as the brain, heart, and ovaries. DCI is preferentially found in the liver and skeletal muscle, i.e., tissues that store glucose [s2]. Both isomers are embedded in the inositol phosphoglycan (IPG) signaling cascade of the cell membrane, which is involved in insulin signal transduction [s1]. Insulin stimulates the enzymatic, irreversible conversion of myo-inositol to D-chiro-inositol [s3]. In insulin resistance, this conversion is impaired, leading to a relative DCI deficiency in peripheral tissues [s5]. Clinically, inositol is best studied in polycystic ovary syndrome (PCOS). The combination MI + DCI at a 40:1 ratio — corresponding to the physiological ratio in human plasma — has demonstrated improvements in menstrual regularity, ovulation rate, androgen excess, and insulin sensitivity in several RCTs [s6, s7]. For psychiatric indications (depression, panic disorder, OCD), older RCTs and a meta-analysis exist showing moderate effects [s8, s9]. Meaningful RCT data support a reduction in gestational diabetes risk [s10, s11]. The glucose-lowering effect was confirmed in a systematic analysis of 16 RCTs [s12].
Legal Status (DE)
In the DACH countries, myo-inositol and D-chiro-inositol are fully marketable as over-the-counter dietary supplements (food supplements) without requiring a drug approval procedure [s14, s15]. No approved EFSA health claims for inositol-specific effects are recorded in the EU register [s13].
Mechanism of Action
Myo-inositol and D-chiro-inositol act as intracellular second messengers in the insulin signaling pathway [s1, s2]. They are precursors of inositol phosphoglycans (IPGs), which are released from the cell membrane upon insulin binding to its receptor and activate downstream enzymes: - DCI-IPG activates pyruvate dehydrogenase, which regulates glucose catabolism via glycolysis [s5, s12]. - MI-IPG regulates glucose uptake via GLUT transporters and influences non-oxidative glucose utilization [s1, s12]. In the ovary, myo-inositol acts as a second messenger for FSH (follicle-stimulating hormone): it transduces the FSH signal at the cell surface into intracellular responses required for oocyte maturation [s3]. MI deficiency in ovarian follicles therefore impairs FSH signal transduction [s3]. In insulin resistance, the enzymatic conversion of MI to DCI is disrupted. Insulin stimulation normally drives the irreversible conversion of MI to DCI; in resistance, this process fails, generating local DCI deficits [s3, s5]. In the CNS, inositol influences the phosphatidylinositol signaling pathway, which plays a role in the transduction of serotonin, dopamine, and noradrenaline signals. This accounts for the psychiatric effects observed in panic disorder, OCD, and depression [s8, s9]. The inositol depletion model proposes that lithium (a mood stabilizer) exerts part of its effect via inositol depletion, implying a feedback loop between inositol availability and neuronal excitability [s8].
Dosing
PCOS / Hormonstatus (Kombination 40:1)
- Dose
- 2 g myo-inositol + 50 mg D-chiro-inositol (40:1 ratio)
- Frequency
- 2× täglich
- Route
- oral
- Duration
- 3–6 Monate
- Timing
- Morning and evening, preferably fasted or with a small meal
- With food
- optional
PCOS / Insulinresistenz (Myo-Inositol Monotherapie)
- Dose
- 4 g myo-inositol
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- 3–6 Monate
- Timing
- Morning and evening
- With food
- optional
Psychiatrische Indikationen (OCD, Panikstörung, Depression)
- Dose
- 12–18 g inositol
- Frequency
- täglich aufgeteilt auf mehrere Dosen
- Route
- oral
- Duration
- 4–6 Wochen
- Timing
- Distributed evenly throughout the day
- With food
- empfohlen
Prävention Gestationsdiabetes
- Dose
- 2 g myo-inositol + 200 µg folic acid
- Frequency
- 2× täglich
- Route
- oral
- Duration
- ab erstem Trimester bis Entbindung
- Timing
- morning and evening
- With food
- empfohlen
In clinical studies, doses up to 18 g/day have been used for psychiatric indications without serious adverse effects [s8]. For metabolic and PCOS indications, 4 g/day is well established [s7]. A generally accepted upper limit in the sense of a tolerable upper intake level (UL) has not been formally established by EFSA or BfR. Gastrointestinal complaints occur regularly above >12 g/day [s16].
The 40:1 ratio (MI:DCI) corresponds to the physiological plasma ratio in humans and demonstrated superior hormonal and metabolic outcomes compared to monotherapies in RCTs [s6, s7]. Pure D-chiro-inositol at high doses may elevate androgen levels in PCOS patients and should not be used alone at high doses [s2].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Meteorismus, Blähungen, weicher Stuhl Occur primarily at doses >12 g/day, osmotic effect in the intestine. Less frequent at PCOS-typical doses (2–4 g/day) [s16]. | häufig | leicht |
| Übelkeit, Bauchkrämpfe Reported in clinical trials for psychiatric indications at high doses (12–18 g); reducible by administration with meals [s8, s16]. | gelegentlich | leicht |
| Tagesmüdigkeit / Schläfrigkeit Reported sporadically by users in online communities, particularly at the start of use [c3]. Not documented as a significant adverse effect in clinical studies. | gelegentlich | leicht |
| Haarausfall (unter hochdosiertem D-Chiro-Inositol) Isolated reports in PCOS communities; mechanistically plausible via possible androgen elevation under isolated DCI [s2, c2]. | selten | leicht |
| Kopfschmerzen Rarely reported in psychiatric inositol studies; no clear mechanism established [s8]. | selten | leicht |
| Schlafstörungen bei abendlicher Einnahme hoher Dosen Theoretically possible via CNS activation at very high doses; not systematically investigated in clinical studies [s8]. | selten | leicht |
Contraindications
Inositol influences the phosphatidylinositol signaling pathway, which is also a target of lithium. Theoretical risk of triggering mania; a small study did not exclude such an effect [s8].
Myo-inositol is considered safe in GDM prevention studies [s10, s11]; however, uncontrolled high-dose use without medical supervision is not recommended due to insufficient long-term data [s17]. Adequate safety data for DCI during pregnancy are lacking.
Inositol acts on the same signaling pathway as lithium (phosphatidylinositol pathway); combination could attenuate or modulate lithium's effect [s8].
Interactions
Synergistic
Combination of myo-inositol + folic acid was more effective than folic acid alone for GDM prevention in RCTs [s10, s11].
Myo-inositol demonstrated similar effects on ovulation induction as metformin in studies, with a more favorable side effect profile; combination theoretically additive in PCOS, however insufficiently evaluated in RCTs [s7].
Inositol and berberine act synergistically in PCOS – both improve insulin sensitivity and hormonal balance via complementary mechanisms. A prospective study showed that myo-inositol improves endocrine parameters, while berberine additionally exerts positive effects on the lipid profile and body composition.
The combination of myo-inositol and alpha-lipoic acid (ALA) improved insulin sensitivity and waist circumference in women with metabolic syndrome and PCOS more effectively than either substance alone in RCTs. Both substances independently activate GLUT-4 vesicles at the cell membrane.
Caution
Inositol may antagonize lithium at the phosphatidylinositol signaling pathway. Psychiatric patients on lithium should take inositol only under medical supervision [s8].
Inositol improves insulin sensitivity [s12]; an additive blood glucose-lowering effect is possible when taken concomitantly with antidiabetic agents. Blood glucose should be monitored more closely [s12].
High doses of inositol hexaphosphate (IP6) can inhibit intestinal absorption of zinc and other essential minerals, potentially leading to nutrient deficiencies. Myo-inositol at low therapeutic doses is less problematic, but a time interval between intake and mineral supplementation is advisable.
Similar to zinc, inositol hexaphosphate (IP6) can inhibit iron absorption. The risk is lower at therapeutic myo-inositol doses; nevertheless, IP6-containing inositol should not be taken simultaneously with iron supplements.
Studies
Tier A — High Evidence
Outcome: Hormonal and metabolic parameters in PCOS (phenotype A), 40:1 MI+DCI vs. placebo
Effect Size: Significant improvement in testosterone, insulin, and cycle regularity (p<0.05)
Outcome: PCOS hormonal status and ovulation rate under myo-inositol
Effect Size: Significant reduction in LH, testosterone, insulin; improvement in ovulation rate
Outcome: Depression, panic disorder, OCD – symptom reduction under inositol vs. placebo
Effect Size: Moderate effects in panic disorder and OCD; no significant overall effect in depression
Outcome: Fasting glucose, insulin, HOMA-IR under inositol
Effect Size: Significant glucose reduction independent of weight loss; improved HOMA-IR
Outcome: Incidence of gestational diabetes in high-risk patients
Effect Size: Significant reduction in GDM incidence under MI + folic acid vs. folic acid alone
Tier B — Moderate Evidence
Outcome: Fertility, oocyte quality, and GDM incidence under myo-inositol
Effect Size: Improvement in clinical pregnancy rate and GDM reduction
Outcome: Panic disorder: panic attacks/week under inositol vs. fluvoxamine
Effect Size: Inositol showed comparable efficacy to fluvoxamine in panic disorder
Tier C — Low Evidence
Outcome: DCI deficiency in insulin resistance and type 2 diabetes
Effect Size: Linear correlation between DCI excretion and degree of insulin resistance
Community Evidence
Top reported benefits
- Normalization of the menstrual cycle in PCOS
- Improved insulin sensitivity and weight loss
- Mood improvement and reduced anxiety
- Improved sleep quality (isolated reports)
- Reduction of OCD symptoms at high dosage
Top reported issues
- Flatulence and loose stools, especially at the beginning
- Nausea and gastrointestinal discomfort at high doses
- Daytime drowsiness during the adjustment phase
- Hair loss in some female users (particularly with DCI)
- No noticeable effect in some female users
Some users in r/PCOS report that isolated D-chiro-inositol can raise androgen levels and trigger hair loss [c2]. Confusion between MI and DCI or incorrect ratios appears to be a common mistake. Onset of effect often only after 4–8 weeks, which leads some users to discontinue prematurely [c1, c4].
Scientific Sources
- D-Chiro-Inositol Regulates Insulin Signaling in Human Adipocytes
Giordano D, Corrado F, Santamaria A, et al. (2021). Frontiers in EndocrinologyBDOI - Myo-inositol as a Key Supporter of Fertility and Physiological Gestation
Dinicola S, Unfer V, Facchinetti F, et al. (2021). NutrientsBPMID:34208684DOI - Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis
Mohammadi F, Mohebi A, Heshmati M, et al. (2025). Frontiers in EndocrinologyALink - Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials
Croze ML, Vella RE, Piler C (2018). Clinical NutritionADOI - EU Register of Nutrition and Health Claims
European Commission (2024). Official Journal of the European Union / EC Food Safety PortalALink - Fragen und Antworten zu Nahrungsergänzungsmitteln – BfR
Bundesinstitut für Risikobewertung (BfR) (2023). BfRALink - BVL – Nahrungsergänzungsmittel
Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) (2023). BVLALink - Inositol: Benefits, dosage, and side effects
Examine.com editorial team (2024). Examine.comDLink - Inositol – Die Wirkung und Nebenwirkungen
Zentrum der Gesundheit Redaktion (2023). Zentrum der GesundheitCLink - Inositol safety: clinical evidences
Nordio M, Basciani S, Camajani E (2019). European Review for Medical and Pharmacological SciencesBLink - Controlled trials of inositol in psychiatry
Levine J (1997). European NeuropsychopharmacologyBPMID:9169302DOI - Myoinositol and D-Chiro Inositol in Improving Insulin Resistance in Obese Male Children: Preliminary Data
Mancini M, Zanardo F, Di Paolo V, et al. (2016). International Journal of EndocrinologyAPMID:27642306DOI - GRAS Notice 1198 – Inositol (21 CFR §184.1370)
U.S. Food and Drug Administration (2023). FDAALink - The Clinical Use of Myo-Inositol in IVF-ET: A Position Statement from the Experts Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS), the Polish Society of Andrology, and the International Scientific Association for the Support and Development of Medical Technologies
Wdowiak A, Bakalczuk S, Filip M, Laganà AS, Unfer V (2025). Journal of Clinical MedicineCDOI - Inositol – Wikipedia
Wikipedia contributors (2024). WikipediaCLink - D-Chiro-Inositol Glycans in Insulin Signaling and Insulin Resistance
Larner J, Brautigan DL, Thorner MO (2010). Molecular MedicineBPMID:20811656DOI - D-Chiro-Inositol – Its Functional Role in Insulin Action and Its Deficit in Insulin Resistance
Larner J (2002). Journal of Diabetes Science and TechnologyBPMID:11900279 - The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A
Unfer V, Facchinetti F, Orrù B, et al. (2024). PubMed / FrontiersAPMID:38295772 - Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer V, Carlomagno G, Dante G, et al. (2017). Endocrine ConnectionsAPMID:29061845DOI - A meta-analysis of inositol for depression and anxiety disorders
Mukai T, Kishi T, Matsuda Y, et al. (2014). Human Psychopharmacology: Clinical and ExperimentalAPMID:24424706DOI - Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder
Benjamin J, Levine J, Fux M, et al. (2000). Journal of Clinical PsychopharmacologyAPMID:11386498
Community Sources
Storage
Unopened
Store in a dry place at room temperature, protected from direct sunlight and moisture.
Opened
Keep container tightly closed; protect powder form especially from moisture. Use within the period indicated on the packaging.
Notes
Inositol is a stable compound; no special refrigeration required. Capsules and powder are equally stable.